pertuzumab + trastuzumab + nab-paclitaxel

The combination of pertuzumab, trastuzumab, and nab-paclitaxel is a treatment regimen used primarily for HER2-positive breast cancer. This combination brings together two targeted HER2 inhibitors (pertuzumab and trastuzumab) with a chemotherapy agent (nab-paclitaxel) to provide a more complete blockade of HER2-mediated signaling while delivering cytotoxic effects. ## Mechanism of Action This regimen combines three distinct medications with complementary mechanisms: **Pertuzumab** is a humanized monoclonal antibody that prevents the dimerization of HER2 with other HER receptors, particularly blocking the formation of the potent signaling heterodimer HER2/HER3[10]. It binds to the extracellular domain of HER2 at a different epitope than trastuzumab. **Trastuzumab** was the first recombinant humanized monoclonal antibody approved for HER2-positive breast cancer[2]. It binds to a different region of the HER2 receptor than pertuzumab, providing complementary inhibition. **Nab-paclitaxel** (albumin-bound paclitaxel, also known by the brand name Abraxane) is a solvent-free, human albumin-stabilized formulation of paclitaxel that works as a cytotoxic agent to kill tumor cells or stop them from growing[9]. ## Clinical Applications This combination is used in several clinical contexts: 1. **Neoadjuvant Treatment**: Given before surgery to shrink tumors in patients with locally advanced HER2-positive breast cancer, including inflammatory breast cancer (IBC)[4][7]. 2. **Metastatic Setting**: Used as a treatment for unresectable locally recurrent or metastatic HER2-positive breast cancer[5]. The regimen has shown promising efficacy in clinical trials. The GeparSepto trial demonstrated that nab-paclitaxel in combination with trastuzumab and pertuzumab significantly increased pathological complete response (pCR) rates compared with solvent-based paclitaxel in HER2-positive breast cancer[6]. ## Administration The typical administration schedule involves: - **Nab-paclitaxel**: 260 mg/m² via intravenous infusion over 30 minutes on day 1 of each 21-day cycle[8]. - **Pertuzumab**: Initial loading dose of 8 mg/kg as a 90-minute intravenous infusion, followed by maintenance doses of 6 mg/kg as 60-minute infusions[8]. - **Trastuzumab**: Loading dose administered over 90 minutes, with subsequent infusions over 30 minutes if no previous infusion reactions occurred[5]. ## Ongoing Research As of May 2025, research continues to evaluate this combination's efficacy and safety. A study is currently evaluating the addition of pyrotinib (an anti-HER2 tyrosine kinase inhibitor) to this regimen to potentially enhance outcomes in HER2-positive breast cancer[1]. The combination of pertuzumab, trastuzumab, and nab-paclitaxel represents an important treatment option for patients with HER2-positive breast cancer, offering the potential for improved outcomes through comprehensive HER2 pathway blockade combined with effective chemotherapy.

Brand names

Abraxane + Herceptin + Perjeta

Other names

albumin-bound paclitaxel + trastuzumab + pertuzumabNPAC(W)+PERT+TRAS (regimen abbreviation)